Loading
Japanese surgeon who was lead author of CheckMate 648, which established nivolumab-based first-line treatment for advanced oesophageal squamous-cell carcinoma.
Yuichiro Doki is professor of gastroenterological surgery at Osaka University. He was first author of the 2022 New England Journal of Medicine report of CheckMate 648, which showed that nivolumab plus chemotherapy and nivolumab plus ipilimumab both lengthened survival compared with chemotherapy alone in untreated advanced oesophageal squamous-cell carcinoma. He has led Japanese surgical and perioperative trials in oesophageal cancer.
| Title | Journal | Year |
|---|---|---|
| CheckMate 648: nivolumab combination therapy in advanced oesophageal squamous cell carcinoma | New England Journal of Medicine | 2022 |
Shares Oesophageal cancer and the tags oesophageal, surgery, trialist.
Shares Oesophageal squamous cell carcinoma, Oesophageal cancer and the tags oesophageal, trialist.
Shares CheckMate 648: nivolumab combination therapy in advanced oesophageal squamous cell carcinoma, Oesophageal squamous cell carcinoma, Oesophageal cancer.
Shares Oesophageal cancer and the tags oesophageal, trialist.
Shares the tags surgery, trialist.
Shares the tags surgery, trialist.
Shares the tags surgery, trialist.
Shares the tags surgery, trialist.